Mark Sheptoff Financial Planning LLC Makes New $35,000 Investment in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mark Sheptoff Financial Planning LLC bought a new stake in ADMA Biologics, Inc. (NASDAQ:ADMA) in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 2,050 shares of the biotechnology company’s stock, valued at approximately $35,000.

Several other hedge funds have also made changes to their positions in ADMA. Larson Financial Group LLC purchased a new stake in ADMA Biologics during the 3rd quarter valued at approximately $31,000. National Bank of Canada FI purchased a new stake in shares of ADMA Biologics during the third quarter worth approximately $35,000. GAMMA Investing LLC lifted its holdings in shares of ADMA Biologics by 106.6% during the fourth quarter. GAMMA Investing LLC now owns 1,874 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 967 shares during the period. Vision Financial Markets LLC purchased a new position in ADMA Biologics in the 4th quarter valued at $51,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics in the 3rd quarter valued at $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $25.00 target price on shares of ADMA Biologics in a report on Tuesday, March 4th.

ADMA Biologics Trading Down 0.5 %

NASDAQ:ADMA opened at $20.22 on Wednesday. ADMA Biologics, Inc. has a 1 year low of $5.90 and a 1 year high of $23.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a fifty day moving average price of $16.91 and a two-hundred day moving average price of $18.10. The stock has a market capitalization of $4.78 billion, a price-to-earnings ratio of 72.21 and a beta of 0.60.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.